For more information, availability and pricing options for sponsorship/exhibition opportunities at the event, please contact Jon Liong at firstname.lastname@example.org.
QuintilesIMS (NYSE:Q) is a leading integrated information and technology-enabled healthcare service provider worldwide, dedicated to helping its clients improve their clinical, scientific and commercial results. Formed through the merger of Quintiles and IMS Health, QuintilesIMS’s approximately 50,000 employees conduct operations in more than 100 countries. Companies seeking to improve real-world patient outcomes and enhanced clinical trial outsourcing through treatment innovations, care provision and access can leverage QuintilesIMS’s broad range of healthcare information, technology and service solutions to drive new insights and approaches. QuintilesIMS provides solutions that span clinical to commercial bringing clients a unique opportunity to realize the full potential of innovations and advance healthcare outcomes.
As a global leader in protecting individual patient privacy, QuintilesIMS uses healthcare data to deliver critical, real-world disease and treatment insights. Through a wide variety of privacy-enhancing technologies and safeguards, QuintilesIMS protects individual privacy while managing information to drive healthcare forward. These insights and execution capabilities help biotech, medical device, and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders in the development and approval of new therapies, identify unmet treatment needs and understand the safety, effectiveness and value of pharmaceutical products in improving overall health outcomes. To learn more, visit www.QuintilesIMS.com.
Established in 1989, OrbiMed is the world’s largest healthcare and life sciences-dedicated investment firm. OrbiMed manages approximately USD$15 billion assets, including several PE/VC funds, hedge funds and mutual funds. Since the inception of its private equity investment activities in 1993, OrbiMed has successfully invested in over 200 private companies across a wide range of therapeutic categories and stages of development, over 100 of which have been either listed or acquired. OrbiMed has continued strong performance in public equity as well. OrbiMed’s investment team includes over 80 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed Asia, with offices in Shanghai and Mumbai, manages OrbiMed Asia Partners (OAP), the first pan-Asia healthcare and life sciences-dedicated private equity fund. OAP has made PE investments in 29 companies, with close to USD$500 million under management. OrbiMed has also invested over USD$1 billion in the stocks of Asia public healthcare companies. For More information, please vist www.orbimed.com.
Protech Pharmaservices Corporation (also known as PPC group) was found in 1997, provides professional services for clinical studies to pharmaceutical and biotechnology companies. PPC group offers clinical and laboratory services in China, Taiwan, Korea and Japan. Since 1997, PPC has completed over 2000 early phase trials, including innovative phase 1 pharmacokinetic, generic bioequivalence and biosimilar studies, to pharmaceuticals companies. In addition, PPC group has conducted over 400 innovative late phase trials, covering all 24 therapeutic arenas. PPC clinical center is the only one that passed all major regions regulatory inspection, including PMDA (Japan), ANSM (European Union), NCPB (Association of Southeast Asian Nations) and US FDA. The bioanalytical laboratory has developed more than 300 drugs’ BioA methods; providing high quality service to local and global clients. To fulfill harmonized bioequivalence standard for phase 1 clinical site, PPC group has set up a phase 1 center in Taipei McKay memorial Hospital in 2012; and co-found a phase 1 center with Xuzhou medical hospital in early 2017.
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 47 countries and more than 18,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health. For more information, visit www.ppdi.com.
ADICON employs its 19 clinical labs and networks across China to provide clinical testing services for clinical studies and trials. As the rst local central lab, accredited by CAP, CMA, ISO 15189, and NGSP, we have successfully delivered dozens of projects with high quality, exibility, and reasonable costs in the past 10 years.
In the era of ever-changing diagnostic technologies and precision medicine, ADICON is keen to catch the frontier of companion diagnosis. With the cutting-edge platforms and experienced teams, we have been working with pharmaceutical partners to deliver novel biomarker analysis services to optimize the patient selection, clinical response, and follow-up monitoring. We welcome you to discuss such opportunities and hear your opinions in ChinaTrials.
Established in 2008 in Xiamen and dedicated to precision oncology, Amoy Diagnostics Co., Ltd. (AmoyDx) provides state-of-the-art molecular diagnostic products and services to vari- ous customers including but not limited to healthcare providers, academic institutions and pharmaceutical companies AmoyDx has a rich portfolio of CFDA&CE registered test kits that mainly focuses on oncology target therapy companion diagnostics AmoyDx has been a well established brand globally, having over 70% of the market share in China in this eld, and the products used in over 40 countries world-wide It is oncology companion diagnostics partner of several major multi-international phar- maceuticals
Beijing Bioknow Information Technology Co., Ltd, founded in 2007, is dedicating to provide integrated eClinical solutions and services in China. Based on BioKnow Universal Application Platform (Bioknow-UAP), Bioknow has developed a series of electric clinical software (Bioknow eClinical Solution), including electronic data capture system (EDC), randomization and trial supply management system (RTSM), electronic patient reported outcomes (ePRO), clinical data reporting system (DMReport), medical coding system (Medcoding), Pharmaco vigilance (PV), clinical trial management system (CTMS), clinical data total management system (CDTMS), electric trial master file (eTMF), pre-clinical research management system（CRMS）and electric common technical documents（eCTD）. Bioknow eClinical Solution integrates the whole process of clinical research and development projects to effectively support clinical development. Bioknow plays a leading role as service provider in information technology in clinical research in China.
Since its establishment in 1992 in Tokyo, Japan, CMIC has been leading CRO (Contract Research Organization) business in the country and has been expanding its geographical coverage in Asia, such as China, Taiwan, Hong Kong, South Korea, Singapore, Malaysia, Thailand, Philippines and Vietnam, the most rapidly growing market in the world.
This makes CMIC able to manage global/Asian clinical trials with hands-on experiences and expertise to provide our clients with the value-added services to support Phase I-IV clinical trials in various therapeutic areas. Not only providing clinical monitoring, data management, statistical analysis, project management, but also investigational drug and medical device development strategic and regulatory affairs consultation which requires strong communication and networking skills with regulatory authorities as well as deep knowledge of regulatory affairs.
Our scope of services is not limited to clinical CRO business, but encompasses R&D value-added business functions as non-clinical CRO, Contract Development and Manufacturing Organization (CDMO) and Contract Sales Organization (CSO).
FOUNTAIN MEDICAL DEVELOPMENT
Fountain Medical Development Ltd. is a contract research organization (CRO) dedicated to offering a full range of ICH GCP-compliant clinical research services for clients conducting clinical research in China, United States, Europe, Japan, Australia, India, Philippines, Taiwan and other regions. The company has over 1400 employees in Asia, Americas, and Europe. FMD’s services include Regulatory Affairs, Phase I-IV clinical trials, Data Management and Biostatistics, Project Management, Medical Writing, Medical Translation, Safety & Pharmacovigilance, Consulting and Pharmacoeconomic studies. The senior management team has decades of combined experiences working with the world’s leading CROs and drug companies. Our extensive global experience in multiple therapeutic areas is unparalleled among other local CROs. FMD has conducted more than 200 clinical trial in China, Hong Kong, Taiwan, Korea, Japan, Armenia and the US. We have good partnership with more than 300 sites in Asia and have enrolled more than 80,000 patients in clinical trials. FMD’s highly skilled team, strategic insights, and experiences in managing complex trials make it your trusted CRO of choice.
Guangzhou KingMed Cold Chain Logistics
We specialize in door to door, customized, time limited cold chain logistics services in some areas such as clinical testing, biological medicine, life science, pharmaceutical research and development, clinical research and IVD.
Through 21 years’experience accumulation, KingMed Cold Chain Logistics has built up a strong service network which covers 31 provinces with 90% population and owned more than 2200 professional employees, 2027 logistics sites serving for 19000 medical institutions every day.
The existing operating platform of the company adopts modern information management mode, and the whole life process monitoring of product is realized through the combination of GPS positioning and precise temperature control.
Jsure Health is the leading patient recruitment organization (PRO) and SMO company in China Jsure provide reliable service raging from feasibility study, patient recruitment, pa- tient retention CRCs deployment With multiple channels, Jsure has helped over 40 studies every year to recruit thousands patients and assist sponsors to speed up their trial progress
Jsure currently has over 200,000 patient database and provide “Drug Finder” for each clinical trial access for patients and referral doctors Jsure has formed the unique PRO+CRC one stop service model to improve both speed and quality of a clinical trial Jsure co-founded Asian patient recruitment organization (APRO) in 2014 to meet the increasing demand of Clinical Trials in Asia In 2015 Jsure health was listed on China new three board
As a pioneering and leading commercial clinical laboratory in China, KingMed is accredited by CAP (13 disciplines), ISO15189, ISO/IEC17025, ISO9001, NGSP Level 1 Laboratory, and follows GLP, US 21 CFR Part 11, ICH-GCP and other applicable laws and regulations. With its remarkable degree of advanced technology and research capabilities, KingMed is currently able to provide more than 2,300 clinical test items. Through our nationwide network of 33 primary laboratories located in the provincial capital cities, KingMed provides clinical tests, consumable materials management, logistic service and specimen management services for clinics, hospitals, international pharmaceutical companies, CROs and biotech companies. www.kingmed.com.cn
Marken provides complete logistics solutions to life sciences & pharmaceutical industry and is the only patient-centric supply chain organization. Our organization manages over 50,000 drugs and biological samples shipments a month. In addition, Marken offers state-of-the-art GMP compliant depot network & logistics across the world.
PRA HEALTH SCIENCES
PRA Health Sciences delivers innovative drug development solutions that improve patients’ lives. Our people love what they do, working tirelessly for clients across all phases and therapeutic areas. With 12,000+ employees covering 80+ countries, we provide an impressive global presence and in-depth knowledge of local regulations, standards of care and cultural customs.
PRA’s Strategic Solutions Division (formerly known as “RPS”) maintains a sole focus on delivering practical, customized outsourcing solutions that seamlessly enhance our clients’ infrastructure. Our unique Embedded Solutions™ model provides people, processes, systems and expertise to efficiently develop internal product portfolios, enhance quality and improve efficiency, while sponsors maintain strategic control.
Schlafender HaseSchlafender Hase® is the global leader in computer-driven proofreading. Our Text Verification Tool® (TVT) is the international benchmark for accurate and user friendly text and graphic verification. TVT is currently used by the world’s leading pharmaceutical and medical device companies as well as numerous regulatory bodies to ensure compliant, error-free and consistent documents. TVT allows users to compare text and graphics with one solution. It is ISO 9001:2008 certified, 21 CFR Part 11 and Annex 11 compliant.
Hangzhou Tigermed Consulting Co., Ltd（stock symbol: 300347） is a leading Contract Research Organization (CRO) in China dedicated to provide professional full clinical trial services. Since inception in 2004, Tigermed has been committed to accelerating medical product development with costs efficiency and quality.
Headquartered in Hangzhou, Tigermed operates 33 subsidiaries, 60 offices across China and 10 overseas offices in Hong Kong, Taiwan, USA, Canada, Korea, Australia, Japan, Malaysia, Singapore and India with over 3200 full time staffs. Tigermed has set up international standard SOPs and serviced more than 600 local and global clients in the conduct of over 920 clinical trials. Tigermed is recognized as “The Innovative CRO” in China，owning to our involvement of 130 innovative drugs.
For more information about Tigermed, please visit www.tigermed.net
Veeva SystemVeeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 525+ customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America.